These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 21703309)

  • 1. Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells.
    Yon C; Viswanathan P; Rossignol JF; Korba B
    Antiviral Res; 2011 Sep; 91(3):233-40. PubMed ID: 21703309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication.
    Korba BE; Montero AB; Farrar K; Gaye K; Mukerjee S; Ayers MS; Rossignol JF
    Antiviral Res; 2008 Jan; 77(1):56-63. PubMed ID: 17888524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
    Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR
    Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
    Korba BE; Elazar M; Lui P; Rossignol JF; Glenn JS
    Antimicrob Agents Chemother; 2008 Nov; 52(11):4069-71. PubMed ID: 18710916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants.
    Ivanisenko NV; Mishchenko EL; Akberdin IR; Demenkov PS; Likhoshvai VA; Kozlov KN; Todorov DI; Gursky VV; Samsonova MG; Samsonov AM; Clausznitzer D; Kaderali L; Kolchanov NA; Ivanisenko VA
    PLoS One; 2014; 9(3):e91502. PubMed ID: 24643004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA.
    Lam AM; Espiritu C; Bansal S; Micolochick Steuer HM; Zennou V; Otto MJ; Furman PA
    J Virol; 2011 Dec; 85(23):12334-42. PubMed ID: 21957306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.
    Lu L; Pilot-Matias TJ; Stewart KD; Randolph JT; Pithawalla R; He W; Huang PP; Klein LL; Mo H; Molla A
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2260-6. PubMed ID: 15155230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.
    Sheaffer AK; Lee MS; Hernandez D; Chaniewski S; Yu F; Falk P; Friborg J; Zhai G; McPhee F
    Antivir Ther; 2011; 16(5):705-18. PubMed ID: 21817192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tricistronic hepatitis C virus subgenomic replicon expressing double transgenes.
    Cheng X; Gao XC; Wang JP; Yang XY; Wang Y; Li BS; Kang FB; Li HJ; Nan YM; Sun DX
    World J Gastroenterol; 2014 Dec; 20(48):18284-95. PubMed ID: 25561795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA.
    Pfeiffer JK; Kirkegaard K
    J Virol; 2005 Feb; 79(4):2346-55. PubMed ID: 15681435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation.
    Madan V; Paul D; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 May; 146(5):1361-72.e1-9. PubMed ID: 24486951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor.
    Jiang M; Zhang EZ; Ardzinski A; Tigges A; Davis A; Sullivan JC; Nelson M; Spanks J; Dorrian J; Nicolas O; Bartels DJ; Rao BG; Rijnbrand R; Kieffer TL
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5456-65. PubMed ID: 24982088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.
    Wang C; Huang H; Valera L; Sun JH; O'Boyle DR; Nower PT; Jia L; Qiu D; Huang X; Altaf A; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1350-8. PubMed ID: 22214777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
    Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.
    Troke PJ; Lewis M; Simpson P; Gore K; Hammond J; Craig C; Westby M
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1331-41. PubMed ID: 22203605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.
    Howe AY; Cheng H; Johann S; Mullen S; Chunduru SK; Young DC; Bard J; Chopra R; Krishnamurthy G; Mansour T; O'Connell J
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3327-38. PubMed ID: 18559648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
    Flint M; Mullen S; Deatly AM; Chen W; Miller LZ; Ralston R; Broom C; Emini EA; Howe AY
    Antimicrob Agents Chemother; 2009 Feb; 53(2):401-11. PubMed ID: 18936191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells.
    Ikeda M; Yi M; Li K; Lemon SM
    J Virol; 2002 Mar; 76(6):2997-3006. PubMed ID: 11861865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
    Ali S; Leveque V; Le Pogam S; Ma H; Philipp F; Inocencio N; Smith M; Alker A; Kang H; Najera I; Klumpp K; Symons J; Cammack N; Jiang WR
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4356-69. PubMed ID: 18838588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.
    Lin HM; Wang JC; Hu HS; Wu PS; Wang WH; Wu SY; Yang CC; Yeh TK; Hsu TA; Jiaang WT; Chao YS; Chern JH; Yueh A
    Antimicrob Agents Chemother; 2013 Feb; 57(2):723-33. PubMed ID: 23165461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.